BPC-157, a synthetic peptide derived from human gastric juice, offers a wide range of potential benefits primarily supported by preclinical research in animal models. It promotes tissue repair and regeneration across multiple systems, including musculoskeletal, gastrointestinal, and nervous tissues.
 In musculoskeletal healing, BPC-157 enhances myogenesis, muscle fiber regeneration, and functional recovery after injury, while also improving the healing of tendons, ligaments, and bones by facilitating angiogenesis, reducing fibrosis, and stabilizing neuromuscular junctions.
 It supports collagen synthesis and influences angiogenesis, which contributes to accelerated recovery from sports injuries and chronic conditions like tendonitis or muscle strains.
For gastrointestinal health, BPC-157 protects the gut lining, reduces inflammation, strengthens the mucosal barrier, and aids in healing ulcers, leaky gut syndrome, irritable bowel syndrome (IBS), and inflammatory bowel diseases such as Crohn’s disease and ulcerative colitis.
 It counteracts damage from various noxious agents, including hyperkalemia, hypokalemia, digitalis toxicity, and succinylcholine, by restoring normal heart rhythm and mitigating arrhythmias and muscle damage.
Neuroprotective effects are also documented, with BPC-157 showing potential in treating traumatic brain injury, spinal cord injury, and peripheral nerve damage. It supports recovery from concussive trauma, ameliorates encephalopathies, and helps restore motor function and coordination after spinal cord compression.
 It also modulates neurotransmitter systems, including serotonergic and dopaminergic pathways, and counteracts neurotoxic effects of substances like lidocaine and local anesthetics.
Additionally, BPC-157 exhibits anti-inflammatory properties, reduces oxidative stress by upregulating cytoprotective factors like heme oxygenase-1 and heat shock proteins, and enhances blood flow by promoting nitric oxide production through the Akt-eNOS axis.
 It has been shown to improve blood pressure regulation and muscle strength, and may support overall well-being and recovery.
Despite these promising preclinical findings, BPC-157 is not approved by any major regulatory agency for human use, and human clinical data remain limited to a few pilot studies.
 The World Anti-Doping Agency has banned it in professional sports due to its performance-enhancing potential.
 Concerns about its pro-angiogenic effects raise theoretical risks of promoting cancer, although no adverse effects were reported in preclinical safety studies.
 Its half-life is less than 30 minutes, and it is metabolized in the liver and cleared by the kidneys.